Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
894,199
-
Shares change
-
-111,952
-
Total reported value, excl. options
-
$8,945,000
-
Value change
-
-$1,891,617
-
Number of buys
-
7
-
Number of sells
-
8
-
Price
-
$10.00
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2021
As of 30 Jun 2021 Gain Therapeutics, Inc. - COM (GANX) had 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 894,199 shares of stock of the company.
Largest 10 holders included GREENLIGHT CAPITAL INC, Granite Point Capital Management, L.P., PRELUDE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Telemetry Investments, L.L.C., MILLENNIUM MANAGEMENT LLC, BlackRock Inc., CM Management, LLC, UBS Group AG, and Banque Cantonale Vaudoise.
This table shows 18 institutional shareholders of the security as of 30 Jun 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.